Search for: "Abbott Products, Inc." Results 221 - 240 of 664
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
3 Apr 2017, 2:22 pm by Lawrence B. Ebert
See Abbott Labs. v.Sandoz, Inc., 566 F.3d 1282, 1299 (Fed. [read post]
1 Apr 2017, 11:52 am
These dangers include the misdirection of labeling—dismissing nonlaw as necessarily illegitimate, the obliteration of the fundamental construct of and constraints inherent in the corporate form, the error of conflating regulation with law, the unintended consequence of subverting law through the incorporation of a societal element in lawmaking, the error of denaturing the societal element of corporate codes, and the production of perversity through the formalism of law that masks… [read post]
15 Mar 2017, 1:16 pm by Jonathan A. Hunter
 In the same lawsuit and based on the same allegations of regulatory noncompliance, Abbott and plaintiff Food & Water Watch, Inc. filed a citizen suit under the Outer Continental Shelf Lands Act (OCSLA), seeking an injunction of production from the Atlantis platform. [read post]
15 Mar 2017, 1:16 pm by Jonathan A. Hunter
 In the same lawsuit and based on the same allegations of regulatory noncompliance, Abbott and plaintiff Food & Water Watch, Inc. filed a citizen suit under the Outer Continental Shelf Lands Act (OCSLA), seeking an injunction of production from the Atlantis platform. [read post]
15 Mar 2017, 1:16 pm by Jonathan A. Hunter
 In the same lawsuit and based on the same allegations of regulatory noncompliance, Abbott and plaintiff Food & Water Watch, Inc. filed a citizen suit under the Outer Continental Shelf Lands Act (OCSLA), seeking an injunction of production from the Atlantis platform. [read post]
15 Mar 2017, 1:16 pm by Liskow & Lewis
 In the same lawsuit and based on the same allegations of regulatory noncompliance, Abbott and plaintiff Food & Water Watch, Inc. filed a citizen suit under the Outer Continental Shelf Lands Act (OCSLA), seeking an injunction of production from the Atlantis platform. [read post]
Discussion: In 2014, two specialty pharmacies, Bioscrip and Accredo agreed to pay $15 million and $60 million[6] respectively to resolve allegations that the specialty pharmacies accepted kickbacks in the form of rebates and patient referrals in exchange for promoting certain drugs over competitor products.[7] These allegations were brought by a whistleblower under the FCA. [read post]
18 Jan 2017, 1:05 am by Abbott & Kindermann
In January 2017 Abbott & Kindermann, Inc. will present its 16th annual educational program for clients and colleagues interested in current land use, environmental, and real estate issues affecting commercial and residential development, agriculture, real estate transactions, easements, mining and the construction materials production industry. [read post]
12 Jan 2017, 7:01 am by John Elwood
Amgen Inc., et al., 15-1039 and Amgen Inc. v. [read post]
10 Dec 2016, 11:31 am by Lawrence B. Ebert
Jeffrey-Allan Indus., Inc., 807 F.2d 955, 962 (Fed. [read post]